Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ronald Lieberman

Podiatrist Encinitas, CA Doctor of Podiatric Medicine

NPI 1811986599 CMS profile 82043

1011 Devonshire Dr, Suite F, Encinitas, CA 92024

Open in the dashboard

General payments

$109,004

80 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ronald Lieberman of Encinitas, CA is reported in the CMS Open Payments database as having received $109,004 across 80 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Podiatrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $609 5
2024 General $2,813 7
2023 General $10,702 14
2022 General $92,805 21
2021 General $1,415 21
2020 General $46 2
2019 General $613 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ronald Lieberman
  • Podiatrist median
  • Middle half of Podiatrist
  • National median

In program year 2025, general payments to Ronald Lieberman were reported at $609. Among 4,572 Podiatrist profiles paid that year, the median was $260 and the middle half received between $94 and $777.

Show as a table
Year Ronald Lieberman Podiatrist median Middle half National median
2019 $613 $196 $72–$601 $163
2020 $46 $118 $38–$335 $114
2021 $1,415 $169 $57–$573 $132
2022 $92,805 $220 $74–$782 $149
2023 $10,702 $208 $71–$635 $160
2024 $2,813 $237 $87–$681 $164
2025 $609 $260 $94–$777 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Linvatec Corporation $104,330 5 payments
  2. Organogenesis Inc. $855 30 payments
  3. Treace Medical Concepts, Inc. $790 10 payments
  4. Stryker Corporation $661 7 payments
  5. Boston Scientific Corporation $520 4 payments
  6. Alafair Biosciences,Inc. $177 2 payments
  7. Acera Surgical, Inc. $158 1 payment
  8. Aroa Biosurgery Incorporated $134 1 payment
  9. Zimmer Biomet Holdings, Inc. $132 2 payments
  10. Horizon Therapeutics plc $125 1 payment
  11. Other $1,122 17 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Acquisitions $104,330 5 payments
  2. Food and Beverage $4,311 74 payments
  3. Travel and Lodging $364 1 payment
Products named General payments · program years 2019–2025
  1. AVENGER RADIAL HEAD, +4 STEMS $104,330 5 payments
  2. Lapiplasty System $656 7 payments
  3. Puraply $507 23 payments
  4. Puraply Antimicrobial $348 7 payments
  5. VersaWrap $177 2 payments
  6. LIMFLOW SYSTEM $164 1 payment
  7. FLOWTRIEVER CATHETER, S $162 1 payment
  8. CT THROMBECTOMY SYSTEM KIT $162 1 payment
  9. Restrata Wound Matrix $158 1 payment
  10. VARIAX $145 2 payments
  11. Other $1,844 33 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

66

Median for Podiatry: 160

Drug cost

$550

Median for Podiatry: $2,368

Branded share of claims

0%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ketoconazole Generic 21 $414
Mupirocin Generic 13 $103
Meloxicam Generic 32 $33

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 35 billing codes

Paid by Medicare

$118,011

Of which drugs: $19

Medicare patients

404

Average age 78

Services billed

2,401

229 women, 175 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 66%
Arthritis 57%
Diabetes 26%
Ischemic heart disease 26%
Atrial fibrillation 25%
Osteoporosis 24%
Depression 20%
Chronic kidney disease 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 22 22 $17

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

80 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record